Nevertheless, the NORDIC NEC study demonstrated that response to platinum-based chemotherapy was different among NECs of GEP origin, depending on Ki67: those tumors with a Ki67 < 55% had lower response rate but longer survival outcomes than tumors with a Ki67 ≥ 55% [5]. This evidence concerns the gene MKI67 and neuroendocrine carcinoma.